Boehringer awarded FDA Commissioner’s National Priority Voucher for HERNEXEOS® in HER2 lung cancer
Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...
Scientific studies also reveal that Indian women are more likely to carry mutations such as EGFR, ALK, and ROS1, which are linked to non-small cell lung carcinoma (NSCLC)—a form of cancer increasingly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback